ANALYTICAL QUALITY BY DESIGN (AQBD) APPROACH FOR LIFECYCLE MANAGEMENT OF PHARMACEUTICAL ANALYTICAL METHODS

The pharmaceutical industry has increasingly adopted science- and risk-based approaches to ensure the quality, safety, and efficacy of pharmaceutical products. One of the most widely implemented strategies is Quality by Design (QbD), which emphasises systematic product and process understanding during drug development. Regulatory guidelines from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, particularly ICH Q8 Pharmaceutical Development, ICH Q9 Quality Risk Management, ICH Q10 Pharmaceutical Quality System, and ICH Q11 Development and Manufacture of Drug Substances, encourage the implementation of QbD principles in both drug substance synthesis and formulation development. In parallel, the concept of Analytical Quality by Design (AQbD) has emerged to improve the robustness and reliability of analytical methods throughout their lifecycle. AQbD involves defining an Analytical Target Profile (ATP), identifying Critical Quality Attributes (CQAs), performing risk assessment, and optimizing analytical parameters using Design of Experiments (DoE). This approach helps establish a Method Operable Design Region (MODR) and implement an effective control strategy for consistent analytical performance. The simultaneous application of QbD and AQbD in API synthesis and analytical method development enhances process understanding, minimizes risks, and supports regulatory expectations. Ultimately, these approaches contribute to the development of high- quality pharmaceutical products and facilitate continuous improvement in pharmaceutical manufacturing.